Search results
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 4 days agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Short Interest in Novavax, Inc. (NASDAQ:NVAX) Drops By 15.6%
ETF DAILY NEWS· 3 days agoNovavax, Inc. (NASDAQ:NVAX – Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 31st, there was short interest ...
Jim Cramer Says He's 'Going To Have To Wait' On SoFi, But Recommends This 'Great Little Industrial...
Benzinga· 9 hours agoOn CNBC's “Mad Money Lightning Round,” Jim Cramer said he still can't recommend Twilio TWLO. On June...
FDA asks COVID vaccine makers to target KP.2 strain with updated shots
Reuters· 3 days agoThe U.S. Food and Drug Administration recommended COVID-19 vaccine makers target the KP.2 strain...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News· 2 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update...
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
InvestorPlace via Yahoo Finance· 6 days agoOn Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part...
FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases
Center for Infectious Disease Research and Policy· 3 days agoOn June 5, the FDA's vaccine advisory group recommended a switch to the JN.1 variant, though it held...
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
Zacks via Yahoo Finance· 6 days agoData from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination...
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks via Yahoo Finance· 3 days agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved...
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
AOL· 7 days agoA combination COVID-influenza vaccine is apparently one step closer to hitting the market. Moderna, which is developing the experimental vaccine, announced ...